This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?
by Ahan Chakraborty
Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market gains.
Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?
by Ahan Chakraborty
NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?
by Kinjel Shah
LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $28.59, representing a -1.26% change from its previous close.
Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?
by Kinjel Shah
LLY banks on soaring Mounjaro and Zepbound sales to defend its obesity edge amid intensifying competition.
Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?
by Zacks Equity Research
NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $26.61, representing a +1.88% change from its previous close.
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?
by Sundeep Ganoria
With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.
Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement
by Zacks Equity Research
NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.
Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?
by Ahan Chakraborty
Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?
by Kinjel Shah
Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid growth prospects.
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)
by Kinjel Shah
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?
by Kinjel Shah
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips
by Zacks Equity Research
VKTX's first-quarter earnings miss estimates. The company remains on track to start the late-stage development of its obesity injection before June-end.
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
by Zacks Equity Research
Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.
Viking Therapeutics to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on VKTX's pipeline updates when it reports first-quarter earnings.
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $23.94, representing a +1.44% change from its previous close.
Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?
by Kinjel Shah
Despite its expensive valuation, we suggest investors hold LLY stock as the company boasts solid growth prospects.
Pfizer Halts Obesity Pill Development Amid Safety Concerns
by Zacks Equity Research
PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
by Ahan Chakraborty
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.